February 17, 2026 03:18 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Actor Rajpal Yadav granted interim bail in ₹9-crore cheque bounce case | Learn AI or become redundant: Microsoft India President issues stark message | India’s wholesale inflation rises to 1.81% in January as manufacturing prices surge | 'India at forefront of AI revolution': PM Modi welcomes world leaders to Delhi summit | Rs 5,000 to women ahead of Tamil Nadu polls! Vijay slams Stalin, says: ‘take the money, blow the whistle’ | Modi congratulates Tarique Rahman as BNP clinches majority in Bangladesh polls | Bangladesh Polls: Tarique Rahman-led BNP secures 'absolute majority' with 151 seats in historic comeback | BJP MP files notice to cancel Rahul Gandhi's Lok Sabha membership, seeks life-long ban | Arrested in the morning, out by evening: Tycoon’s son walks free in Lamborghini crash case | ‘Why should you denigrate a section of society?’: Supreme Court pulls up ‘Ghooskhor Pandat’ makers
Covaxin | Bharat Biotech
Image Credit: Pixabay

Bharat Biotech to start Covaxin trials in 2-18 age grp in next 10-12 days: Niti Aayog member

| @indiablooms | May 19, 2021, at 02:13 am

New Delhi/IBNS: Bharat Biotech will launch the phase II and III clinical trials for Covaxin in children between the ages of 2 to 18 years in the next 10-12 days,  Dr VK Paul, member (health) of Niti Aayog, said on Tuesday.

"Covaxin has been approved by the Drugs Controller General of India (DCGI), for Phase II/III clinical trials in the age group of 2 to 18 years. I have been told that trials will begin in the next 10-12 days," Paul said during a press conference, reported Hindustan Times.

On May 11, Drugs Controller General of India's (DCGI) gave its nod to conduct clinical trials in children.

DGCI gave the permission based on the recommendations by the subject expert committee (SEC) of the Central Drugs Standard Control Organisation’s (CDSCO), which signalled the trial subject to certain conditions, the report said.

In February last, Bharat Biotech had approached the DGCI seeking permission for conducting clinical trials in children in the 5-18 age group.

However, the central drug regulator had rejected the proposal and asked the firm to come up with data showing the vaccine's efficacy in adults first.

The US and Canada have already approved the Pfizer-BioNTech shots for ages 12-15 and started vaccinating them from May 14.

Canada,too, had approved the Pfizer jabs for this age group on May 5.

Meanwhile, the European Medical Agency is also measuring the efficacy of the use of Pfizer vaccines in beneficiaries below 18 years of age.

The clinical trials in India are expected to be conducted in 525 participants at multiple hospitals, the HT report said.

AIIMS chief Dr Randeep Guleria had stated the need for quick data and risk-benefit analysis of the Covid-19 vaccine in children. 

Experts across the world have been appealing to the governments across the world to vaccinate children for the schools to reopen safely.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.